RepliCel Life Sciencesの評価平均
RepliCel Life Sciencesの評価平均は何ですか。
RepliCel Life Sciences, Inc.の評価平均は2.00です。
評価平均の定義は何ですか。
Recommendation meanは、株式のアナリストの格付けの平均値で、1.0(強い買い)から5.0(強い売り)の範囲です。
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
TSXVのセクタHealth Careにおける評価平均の企業と比べるRepliCel Life Sciences
RepliCel Life Sciencesは何をしますか。
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
RepliCel Life Sciencesと類似の評価平均
- Cabot Oil & Gasの評価平均は1.96です。
- Truistの評価平均は1.96です。
- Delta Air Linesの評価平均は1.96です。
- Discover Servicesの評価平均は1.96です。
- United Micro Electronicsの評価平均は1.96です。
- Tapestry Incの評価平均は1.97です。
- RepliCel Life Sciencesの評価平均は2.00です。
- Trip.com Ltdの評価平均は2.03です。
- Sherwin-Williams Coの評価平均は2.03です。
- Canadian Pacific Kansas Cityの評価平均は2.03です。
- Arista Networks Incの評価平均は2.03です。
- Anheuser-Busch InBev SA/NVの評価平均は2.03です。
- Celanese Corpの評価平均は2.04です。